Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description
2016
Immunogenicity is known to be one of the main parameters to be considered during evaluation of the safety and efficacy of a biologic drug. The recent introduction in rheumatologic therapy of biosimilar drugs requires the comparison to the correspondent reference product (RP) of all their characteristics, included immunogenicity. In particular, immunogenicity of infliximab (IFX) biosimilar CT-P13 and IFX-RP …
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
4
Citations
NaN
KQI